Evidence map›Paper›PMID 28212527›Full record

Trial reportOncotarget2017

A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer.

Tomonori Yano, Hiroi Kasai, Takahiro Horimatsu, Kenichi Yoshimura, Satoshi Teramukai, Satoshi Morita, Harue Tada, Yoshinobu Yamamoto, Hiromi Kataoka, Naomi Kakushima and 3 more

Open access · diamondAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 119 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Tomonori YanoDepartment of Gastroenterology, Endoscopy division, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroi KasaiInstitute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Takahiro HorimatsuDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kenichi YoshimuraInnovative Clinical Research Center (iCREK), Kanazawa University Hospital, Japan.
Satoshi TeramukaiDepartment of Biostatistics, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Japan.
Satoshi MoritaInstitute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Harue TadaInstitute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Yoshinobu YamamotoDepartment of Gastrointestinal Oncology, Hyogo Cancer Center, Hyogo, Japan.
Hiromi KataokaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Naomi KakushimaEndoscopy Division, Shizuoka Cancer Center, Shizuoka, Japan.
Ryu IshiharaDepartment of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Disieses, Osaka, Japan.
Hajime IsomotoDepartment of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan.
Manabu MutoDepartment of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University Hospital · JPKyoto University · JPHyogo Prefectural Cancer Center · JPKanazawa University Hospital · JPKyoto Prefectural University of Medicine · JPNagasaki University Hospital · JPNagoya City University · JPNational Cancer Center Hospital East · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) showed promising efficacy for local failure after chemoradiotherapy (CRT) for esophageal cancer. However, PDT required long sun shade period. This study aimed to evaluate the safety and efficacy of PDT using second generation photosensitizer, talaporfin sodium for local failure after CRT. This was the multi-institutional non-randomized phase II study. Patients with histologically proven local failure limited within the muscularis propria after 50Gy or more radiotherapy (RT) for esophageal cancer were eligible. We set the primary endpoint as local complete response (L-CR) per patients. And, secondary endpoints were confirmed L-CR, local progression free survival (L-PFS), progression free survival (PFS), overall survival (OS), L-CR per lesions (Lesion L-CR), and confirmed Lesion L-CR. The PDT procedure commenced with intravenous administration of a 40 mg/m2 dose of talaporfin sodium followed by diode laser irradiation at a 664 nm wavelength. 26 eligible patients were enrolled and all were treated with PDT. Twenty three patients with 25 lesions were assessed L-CR after PDT; the L-CR rate per patients was 88.5% (95% CI: 69.8%-97.6%). No skin phototoxicity was observed, and no grade 3 or worse non-hematological toxicities related to PDT were observed. PDT using talaporfin sodium and a diode laser is a safe and curative salvage treatment for local failure after CRT or RT for patients with esophageal cancer.

Indexed as

PhotochemotherapySalvage TherapyAgedAged, 80 and overChemoradiotherapyEsophageal NeoplasmsFemaleFollow-Up StudiesHumansLasers, SemiconductorMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPhotosensitizing AgentsPorphyrinsPhotosensitizing AgentsPorphyrinsTalaporfinchemoradiotherapyesophageal cancerphotodynamic therapysalvage treatmenttalaporfin sodium

Identifiers

PMID28212527
PMCPMC5400653
OpenAlexW2563170362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.